Active Ingredient History

  • Now
Rigosertib is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics. Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.   Wikipedia

  • SMILES: COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1
  • Mol. Mass: 451.5
  • ALogP: 2.8
  • ChEMBL Molecules:
More Chemistry
(n-(2-methyloxy-5-(2',4',6'-trimethoxystyrylsulfonyl)methylenephenyl)amino)acetic acid | n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide | on01910 | on 01910 | on-01910 | on | | rigosertib | rigosertib sodium | sodium (n-(2-methyloxy-5-(2',4',6'-trimethoxystyrylsulfonyl)methylenephenyl)amino)acetate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue